Back to top
more

Palatin Technologies (PTN)

(Delayed Data from AMEX)

$0.93 USD

0.93
256,355

-0.14 (-12.69%)

Updated Nov 15, 2024 03:58 PM ET

After-Market: $0.95 +0.02 (1.69%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Palatin Technologies (PTN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Palatin (PTN) Up 15% on Results From Dry Eye Disease Study

by Zacks Equity Research

A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.

Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?

by Zacks Equity Research

Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -5.88% and 63.32%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -6.78% and 9.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -22.41% and 4.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio, Inc. (TELA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -23.53% and 2.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of -3.17% and 9.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 35.82% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.63% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seer, Inc. (SEER) delivered earnings and revenue surprises of 0% and 6.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 16% and 7.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Swedish Orphan Biovitrum (BIOVF) Beats Q3 Earnings Estimates

by Zacks Equity Research

Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 16.67% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals

by Zacks Equity Research

Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.

Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 0% and 62.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -50% and 7.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 16.13% and 5.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Berkeley Lights, Inc. (BLI) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Berkeley Lights, Inc. (BLI) delivered earnings and revenue surprises of -3.23% and 1.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Curis (CRIS) delivered earnings and revenue surprises of -5.88% and 6.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Inc. (RPTX) Stock Jumps 9.1%: Will It Continue to Soar?

by Zacks Equity Research

Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -33.33% and 78.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -35.61% and 0.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?